| Ahmed M. Hamdy |
Ahmed M. Hamdy is the founder of Vincerx Pharma, Inc. (founded in 2018) and holds the title of Chairman & Chief Executive Officer. Dr. Hamdy is also the founder of Acerta Pharma BV, Acerta Pharma LLC. Dr. Hamdy's current job(s) include being an Independent Director at Andes Biotechnologies SA (since 2016), a Director & Clinical Advisor at Andes Biotechnologies Global, Inc. (since 2016), a Member at AstraZeneca PLC (since 2013), a Member-Presidents Council at The Palo Alto Medical Foundation (since 2016), and a Member-Deans Council at Baskin School of Engineering (since 2019). Dr. Hamdy's former job(s) include being a Medical Director at ALZA Corp. (2004-2006), a Medical Director at Johnson & Johnson (2004-2006), a Senior Principal Scientist at Actavis, Inc. (2000-2004), and a Chief Medical Officer at Pharmacyclics LLC (2008-2011). Dr. Hamdy's education history includes a doctorate from the University of Cairo and an undergraduate degree from KasrAlAiny School of Medicine. |
| Aradhana Sarin |
Aradhana Sarin is currently the Chief Financial Officer & Executive Director at AstraZeneca PLC, President & Director at Achillion Pharmaceuticals, Inc., and an Independent Non-Executive Director at Anheuser-Busch InBev SA. Previously, he worked as an Independent Director at OraSure Technologies, Inc., Managing Director-Healthcare Investment Banking at UBS AG, and MD-Healthcare Corporate & Investment Banking at Citizens, Inc. (Austin, Texas) from 2010 to 2017. He also briefly served as the Executive VP, Chief Strategy & Business Officer at Alexion Pharmaceuticals, Inc. Dr. Sarin holds a doctorate from the University of Delhi and an MBA from Stanford Graduate School of Business. |
| Regina Fritsche Danielson |
Regina Fritsche Danielson is currently the Director at Fluicell AB and also holds a position as SVP, Head-Research & Early Development at AstraZeneca PLC. She holds a doctorate degree from the University of Gothenburg. |
| Cindy L. Hoots |
Cindy L. Hoots is an Independent Director at Zoom Video Communications, Inc. since 2023. She is also the Chief Digital & Information Officer at AstraZeneca PLC since 2020. Previously, she worked as the VP-Next Generation Products & Commercial at British American Tobacco plc from 2016 to 2018, and as the Global Vice President-Technology at Unilever Plc from 2018 to 2019. Ms. Hoots completed her undergraduate degree at DeVry Institute of Technology. |
| Alberto Hegewisch |
Alberto Hegewisch is currently the Chief Medical Officer at AstraZeneca PLC since 2023. He completed his undergraduate degree at Universidad La Salle and his graduate degree at Hibernia College. |
| Sharon Barr |
Sharon Barr has a current job as EVP-BioPharmaceuticals Research & Development at AstraZeneca PLC. |
| Pam P. Cheng |
Pam P. Cheng is an Independent Non-Executive Director at Smiths Group Plc, and Executive VP-Operations & Information Technology at AstraZeneca PLC. She is also a Trustee at Stevens Institute of Technology. Previously, she served as an Independent Director at Codexis, Inc., Senior VP-Global Supply Chain Management at Merck & Co., Inc., and President at MSD China Holding Co. Ltd. Ms. Cheng holds an undergraduate and graduate degree from Stevens Institute of Technology and an MBA from Pace University. |
| Marc Pierre Jean Dunoyer |
Marc Pierre Jean Dunoyer is currently the Chief Executive Officer at Alexion Pharmaceuticals, Inc. He is also the Chairman at AstraZeneca KK. In addition, he holds positions as a Director at AstraZeneca UK Ltd., AstraZeneca Intermediate Holdings Ltd., and Acerta Pharma BV. He is an Independent Director at Orchard Therapeutics (Europe) Ltd. and serves as the Chief Strategy Officer at AstraZeneca PLC. In his former roles, Mr. Dunoyer served as the Chairman at GlaxoSmithKline KK from 2010 to 2013. He was also an Outside Director at JCR Pharmaceuticals Co., Ltd. Additionally, he held the position of Independent Non-Executive Director at Orchard Therapeutics Plc from 2018 to 2024. He served as the President-Asia Pacific at Hoechst Marion Roussel SA. Furthermore, he was the Global Head-Rare Diseases Unit at GSK Plc from 2012 to 2013. Mr. Dunoyer obtained an MBA from Hautes Etudes Commerciales and completed his graduate studies at Université de Paris IV Paris-Sorbonne. |
| Michel Demaré |
Michel Demaré is currently the Chairman at AstraZeneca PLC since 2019. He is also the Deputy Chairman-Supervisory Board at Louis Dreyfus Company Holdings BV since 2014, Chairman-Supervisory Board at International Institute for Management Development, Chairman at Nomoko AG, Non-Executive Director at Vodafone Group Plc since 2018, and a Member at Beirat Zukunft Finanzplatz. In his former positions, Mr. Demaré served as Vice Chairman-Supervisory Board at UBS AG. From 2010 to 2019, he was the Independent Vice Chairman at UBS Group AG. He also held the position of Vice Chairman-Supervisory Board at Syngenta AG in 2012. Mr. Demaré was the Chairman of SwissHoldings from 2013 to 2015 and the Chairman of Syngenta Foundation For Sustainable Agriculture from 2013 to 2017. Prior to that, he was the Chief Financial Officer-Europe Region at Baxter International, Inc. from 2002 to 2005 and the CFO-Global Polyolefins & Elastomers Division at The Dow Chemical Co. from 1997 to 2002. From 2005 to 2013, he served as the Chief Financial Officer at ABB Ltd.Mr. Demaré holds an MBA from Katholieke Universiteit Leuven, which he obtained in 1980. He also has an undergraduate degree from Université Catholique de Louvain, which he received in 1978. |
| José Baselga |
Founder of Venthera, Inc., Mosaic Biomedicals SL and Tango Therapeutics, Inc., José Baselga is an entrepreneur is on the board of Breast International Group and Foghorn Therapeutics, Inc. and Executive VP-Oncology Research & Development at AstraZeneca Plc, Member of Institute of Medicine, Member of Association of American Physicians, Member of American Society of Clinical Investigation and Member of National Academy of Medicine of United States.
Dr. Baselga previously was President for American Association for Cancer Research, Chairman-Hematology & Oncology Division at The General Hospital Corp., Associate Director at Massachusetts General Hospital Cancer Center, President of European Society for Medical Oncology, Chief Medical Officer for Memorial Sloan-Kettering Cancer Center, Director at American Society of Clinical Oncology, Professor at Weill Cornell Medical College, Professor at Harvard Medical School and Director & Chairman-Medical Oncology Service at Vall d'Hebron Institut d'Oncologia.
José Baselga received a doctorate from Autonomous University of Barcelona. |
| Pascal Soriot |
Pascal Soriot is currently the Chief Executive Officer & Executive Director at AstraZeneca PLC. He also holds current positions as the Chief Executive Officer at AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd., AstraZeneca Holding GmbH, and Chairman at AstraZeneca AB. Additionally, he serves as a Director at Pharmaceutical Research & Manufacturers of America and Acerta Pharma BV. In his former roles, Dr. Soriot was the Director & Chief Executive Officer-Roche Group at Genentech, Inc. in 2012. He also served as an Independent Non-Executive Director at CSL Ltd. from 2020 to 2021. Prior to that, he was a Director at Chugai Pharmaceutical Co., Ltd. from 2010 to 2011 and an Independent Director at Viela Bio, Inc. from 2019 to 2020. He held the position of Chief Operating Officer at Roche Pharmaceuticals, Inc. from 2010 to 2012 and Chief Operating Officer at Sanofi-Aventis U.S. LLC in 2006. He was also Vice President-Asia Pacific at Hoechst Marion Rousel JP in 2000 and Manager-District Sales at Roussel NZ Ltd. in 1989. Dr. Soriot's education includes an MBA from École des Hautes Études Commerciales de Paris and a doctorate from École Nationale Vétérinaire d'Alfort. |
| Jeffrey Pott |
Jeffrey Pott is currently working as the CHRO, Chief Compliance Officer & General Counsel at AstraZeneca PLC since 2021. Previously, he served as the Chairman at Aptium Oncology, Inc. and as a Principal at Drinker Biddle & Reath LLP. He completed his undergraduate degree at Wheaton College (Illinois) in 1987 and obtained his graduate degree from Villanova University School of Law in 1990. |
